CLEC9A and neoplasm: In conclusion, by exploring the impact of HLA matching in the NSG system, the PBMC source used for engraftment, and the DC complementation strategies, we have developed two novel humanized mouse models suitable to characterize the immunogenicity and therapeutic efficacy of vaccines targeting HPV antigens expressed by dysplastic skin or delivering diverse tumor antigens to human Clec9A+ DCs in vivo.